Fig. 4. EGFR and EphA2 phosphorylation changes after treatment with ligand and PLC drugs.

(A) Representative Western blots after treatment with EA1 (15 min, 500 ng/ml), 3M3FBS (45 min, 25 μM), or 3M3FBS followed by EA1. (B) Representative Western blots after treatment with U73122 (15 min, 5 μM), EA1 (as above), EGF (15 min, 100 ng/ml), or U73122 followed by each ligand. (C) Quantification of EphA2 pS897 levels in all conditions normalized to the corresponding total EphA2 bands. N = 6 to 12. Statistical analysis was performed using a Kruskal-Wallis test [H(7) = 19.45, P = 0.007] with a Mann-Whitney U test for comparisons between groups. Significance values were adjusted by the Bonferroni correction for multiple tests. (D) Quantification of total EphA2 levels in all conditions normalized to actin. N = 6 to 12. Statistical analysis was performed using a Kruskal-Wallis test [H(7) = 38.44, P = 3.0 × 10⁻⁶] with a Mann-Whitney U test for comparisons between groups. Significance values were adjusted by the Bonferroni correction for multiple tests. *P < 0.05, **P < 0.01, and ***P < 0.001.